154. Epilepsy with continuous spikes and waves during slow sleep Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 7 /  Drugs : 4 - (DrugBank : 3) / Drug target genes : 13 - Drug target pathways : 7

Drugs and their primary sponsors and trial info
N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide   
   Neurocrine Biosciences, Inc.
      -   Phase 2   EUCTR2021-006788-11-DK   Canada;Denmark;France;Germany;Spain;Switzerland;United Kingdom;United States;
NBI-827104   
   Neurocrine Biosciences
      2021   Phase 2   NCT04625101   Denmark;Spain;Switzerland;United States;
   Neurocrine Biosciences, Inc.
      2021   Phase 2   EUCTR2020-003141-11-ES   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003141-11-DK   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      -   Phase 2   EUCTR2021-006788-11-DK   Canada;Denmark;France;Germany;Spain;Switzerland;United Kingdom;United States;
      -   Phase 2   EUCTR2020-003141-11-DE   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;